Abstract
Procathepsin D (pCD) is overexpressed and secreted by cells of various tumor types including breast and lung carcinomas, affecting multiple features of tumor cells including proliferation, invasion, metastasis and apoptosis. As more and more attention has been focused on potential use of pCD in clinical practice, we devoted this paper to summarize the three major potentials of pCD — tumor marker, potential drug and screening agent. Despite more than 20 years of studies and numerous reports of the association between pCD level and tumor size, tumor grade, tumor aggressiveness, and incidence of metastasis, pCD is still not used as a marker of cancer development. This is due to problems in distinguishing between pCD expressed by cancer derived cells and normal tissue cells and in the exact measuring of its different molecular forms (pCD, single chain cathepsin D (CD) and two chain CD) in tumor tissue. Numerous studies demonstrated that pCD secreted from cancer cells affects multiple stages of tumor progression. Subsequent data showing that inhibition of pCD secretion from cancer cells can inhibit cancer cell growth in vitro and in vivo suggested the possibility of using pCD suppression in clinical practice. A third possibility of using pCD in clinical practice is represented by the use of anti-pCD autoantibodies in screening cancer patients or in correlation with the level of these antibodies with the progress of cancer disease. Despite the fact that preliminary findings suggested such correlation, more detailed studies revealed significant setbacks.
Keywords: Antibodies, Aspartic, Autoantibodies, Breast, Cancer, Cathepsin D, Drug, Procathepsin D, Screening
Anti-Cancer Agents in Medicinal Chemistry
Title: Procathepsin D as a Tumor Marker, Anti-Cancer Drug or Screening Agent
Volume: 12 Issue: 2
Author(s): Vaclav Vetvicka and Martin Fusek
Affiliation:
Keywords: Antibodies, Aspartic, Autoantibodies, Breast, Cancer, Cathepsin D, Drug, Procathepsin D, Screening
Abstract: Procathepsin D (pCD) is overexpressed and secreted by cells of various tumor types including breast and lung carcinomas, affecting multiple features of tumor cells including proliferation, invasion, metastasis and apoptosis. As more and more attention has been focused on potential use of pCD in clinical practice, we devoted this paper to summarize the three major potentials of pCD — tumor marker, potential drug and screening agent. Despite more than 20 years of studies and numerous reports of the association between pCD level and tumor size, tumor grade, tumor aggressiveness, and incidence of metastasis, pCD is still not used as a marker of cancer development. This is due to problems in distinguishing between pCD expressed by cancer derived cells and normal tissue cells and in the exact measuring of its different molecular forms (pCD, single chain cathepsin D (CD) and two chain CD) in tumor tissue. Numerous studies demonstrated that pCD secreted from cancer cells affects multiple stages of tumor progression. Subsequent data showing that inhibition of pCD secretion from cancer cells can inhibit cancer cell growth in vitro and in vivo suggested the possibility of using pCD suppression in clinical practice. A third possibility of using pCD in clinical practice is represented by the use of anti-pCD autoantibodies in screening cancer patients or in correlation with the level of these antibodies with the progress of cancer disease. Despite the fact that preliminary findings suggested such correlation, more detailed studies revealed significant setbacks.
Export Options
About this article
Cite this article as:
Vetvicka Vaclav and Fusek Martin, Procathepsin D as a Tumor Marker, Anti-Cancer Drug or Screening Agent, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (2) . https://dx.doi.org/10.2174/187152012799014904
DOI https://dx.doi.org/10.2174/187152012799014904 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Overview of Cantharidin and its Analogues
Current Medicinal Chemistry P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry ZIP4 is a Novel Diagnostic and Prognostic Marker in Human Pancreatic Cancer: A Systemic Comparison Between EUS-FNA and Surgical Specimens
Current Molecular Medicine Topoisomerase I Inhibitors in the Treatment of Primary CNS Malignancies: An Update on Recent Trends
Anti-Cancer Agents in Medicinal Chemistry Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Biological Activities of Eco-Friendly Synthesized Hantzsch Adducts
Medicinal Chemistry Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways
Current Neurovascular Research Extracellular Citrate in Health and Disease
Current Molecular Medicine Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets Neonatal Germ Cell Tumors
Current Pediatric Reviews Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Editorial (Thematic Issue: Chemical and Biological Technology for In Vivo and Molecular Imaging)
Current Topics in Medicinal Chemistry Harnessing the Capacity of Cell-Penetrating Peptides for Drug Delivery to the Central Nervous System
Current Pharmaceutical Biotechnology Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Pharmacological Modulation of Sphingolipids and Role in Disease and Cancer Cell Biology
Mini-Reviews in Medicinal Chemistry The Arrestin Fold: Variations on a Theme
Current Genomics VEGF and HIF in Renal Cell Carcinogenesis
Recent Patents on Biomarkers